Tesamorelin research peptide — wholesale supply

Regulatory positioning: Rx-only · Approved drug. Tesamorelin (Egrifta) is an approved drug in select jurisdictions (US FDA) for HIV-associated lipodystrophy. Rx-only. Supplied as research-grade API against valid prescription.

Overview

Tesamorelin is a 44-amino-acid synthetic analogue of growth hormone-releasing hormone (GHRH), modified at the N-terminus with a trans-3-hexenoic acid group to confer resistance to enzymatic degradation. The compound is supplied as a research-grade lyophilized peptide, intended for in-vitro GHRH receptor research, growth hormone axis pathway studies, and analytical method development. SPK Pharma India supplies Tesamorelin as a documented, lot-traceable research compound for distributors, contract manufacturers, and academic laboratories. The compound is supplied for research and analytical applications only.

Specifications

Research context

Tesamorelin is a well-characterised research tool in the growth hormone axis. The GHRH receptor (GHRHR) is a Class B G-protein-coupled receptor expressed in the anterior pituitary, and the trans-3-hexenoic acid N-terminal modification of Tesamorelin confers resistance to dipeptidyl peptidase IV (DPP-IV) cleavage, which extends the in-vitro half-life of the analogue relative to native GHRH 1-44. In-vitro receptor-binding assays, cAMP signalling studies, and downstream pathway analysis in GHRHR-expressing cell lines are the typical research applications.

The compound is also used as a research comparator to native GHRH 1-44 and to shorter GHRH analogues such as CJC-1295 without DAC, to characterise the contribution of the N-terminal modification to receptor engagement and downstream signalling. SPK Pharma India does not make therapeutic, clinical, diagnostic, or dosing claims for this product. The compound is supplied strictly for in-vitro research, analytical method development, and reference-standard work.

For researchers new to the compound, the standard analytical reference points are CAS 218949-48-5, the 44-amino-acid backbone, the trans-3-hexenoic acid N-terminal modification, the approximate molecular weight of 5,135.78 g/mol, the lyophilized powder form, and the documented purity threshold (≥99% HPLC). The full amino acid sequence is disclosed on the lot-matched COA and on the product specification sheet.

Packaging and supply

• 5 mg research vial — for method development, receptor-binding assays, and reference-standard qualification. Standard MOQ: 5 vials.
• 10 mg research vial — for ongoing research programmes with higher per-assay demand. Standard MOQ: 2 vials.
• 20 mg research vial — for higher-mass research programmes. Standard MOQ: 2 vials.
• Bulk pack — on application, for annual supply contracts and recurring orders.

Distributor pricing is available on application. Annual supply contracts with scheduled recurring dispatch are available for repeat buyers. Lead time for in-stock SKUs is typically 5 business days from purchase order confirmation; lead time for scheduled production is typically 4 to 6 weeks.

Quality and documentation

Every lot of Tesamorelin ships with a lot-matched Certificate of Analysis documenting identity (mass spectrometry and amino acid analysis), purity (HPLC), appearance, lot number, and synthesis batch reference. A representative sample of every lot is independently verified by a third-party analytical laboratory before release. MSDS is supplied with every shipment. The COA template, the lot-traceability workflow, and the third-party verification scope are documented on the Quality page.

Storage and handling

• Store at -20°C in the original sealed container.
• Protect from light and moisture.
• Allow the sealed container to reach room temperature before opening, to avoid condensation.
• Reconstitute in sterile, low-endotoxin research-grade water or in a mild buffer at the working concentration required by the assay.
• Do not refreeze once reconstituted; aliquot and store at working concentration.
• Avoid vigorous vortexing; allow gentle dissolution to minimise aggregation.

Shipping

Tesamorelin is shipped lyophilized in sealed vials within temperature-validated packaging. International lanes are routed through dedicated life-science logistics partners with cold-chain handling. Standard dispatch is within 5 business days of purchase order confirmation. SPK Pharma India ships to the United States, the European Union, the United Kingdom, Canada, MENA, APAC, and LATAM. Full export documentation, including commercial invoice, packing list, certificate of origin, COA, and MSDS, is included with every shipment. Destination-specific documentation is supported on request.

Compliance

Tesamorelin (Egrifta) is an approved drug in select jurisdictions (US FDA) for HIV-associated lipodystrophy. Rx-only. Supplied as research-grade API against valid prescription. SPK Pharma India does not make therapeutic, clinical, diagnostic, or dosing claims for this product. The buyer is responsible for end-use classification in the destination jurisdiction, for the appropriate Rx / licence / controlled-substance documentation, and for ensuring that downstream handling is consistent with the regulatory positioning stated above.

Lead form CTA

To request a wholesale quote for Tesamorelin, contact the trade desk with the subject line "Tesamorelin wholesale quote" and your company details, expected volume, and destination country. Distributor pricing is available on application. The desk responds within one business day.

Related compounds

• CJC-1295 without DAC (Modified GRF 1-29) — 29-amino-acid GHRH analogue research peptide
• Ipamorelin — selective GHS pentapeptide research peptide
• HGH (Somatropin) — 191-amino-acid recombinant research lyophilizate
• IGF-1 LR3 — 83-amino-acid long arginine IGF-1 research peptide
• FOXO4-DRI — 46-amino-acid D-retro-inverso research peptide